.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Daiichi Sankyo
Julphar
Fish and Richardson
Farmers Insurance
Dow
Deloitte
Merck
Covington
Accenture

Generated: December 17, 2017

DrugPatentWatch Database Preview

VELCADE Drug Profile

« Back to Dashboard

When do Velcade patents expire, and when can generic versions of Velcade launch?

Velcade is a drug marketed by Millennium Pharms and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-five patent family members in twenty-five countries and seven supplementary protection certificates in seven countries.

The generic ingredient in VELCADE is bortezomib. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bortezomib profile page.
Drug patent expirations by year for VELCADE

Pharmacology for VELCADE

Drug ClassProteasome Inhibitor
Mechanism of ActionProteasome Inhibitors

Medical Subject Heading (MeSH) Categories for VELCADE

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003RXYesYes► Subscribe► SubscribeY► Subscribe
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003RXYesYes► Subscribe► Subscribe► Subscribe
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003RXYesYes► Subscribe► Subscribe► Subscribe
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003RXYesYes► Subscribe► Subscribe► Subscribe
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003RXYesYes► Subscribe► Subscribe► Subscribe
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003RXYesYes► Subscribe► SubscribeY► Subscribe
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003RXYesYes► Subscribe► SubscribeY► Subscribe
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003RXYesYes► Subscribe► Subscribe► Subscribe
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003RXYesYes► Subscribe► Subscribe► Subscribe
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VELCADE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003► Subscribe► Subscribe
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003► Subscribe► Subscribe
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003► Subscribe► Subscribe
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003► Subscribe► Subscribe
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003► Subscribe► Subscribe
Millennium PharmsVELCADEbortezomibINJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602-001May 13, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for VELCADE

Drugname Dosage Strength RLD Submissiondate
bortezomibFor Injection3.5 mg/vialVelcade11/20/2008

Non-Orange Book Patents for Tradename: VELCADE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,747,150 Boronic ester and acid compounds, synthesis and uses► Subscribe
6,699,835 Formulation of boronic acid compounds► Subscribe
6,066,730 Boronic ester and acid compounds, synthesis and uses► Subscribe
7,119,080Boronic ester and acid compounds, synthesis and uses► Subscribe
7,109,323Formulation of boronic acid compounds► Subscribe
7,531,526Boronic ester and acid compounds, synthesis and uses► Subscribe
6,617,317 Boronic ester and acid compositions► Subscribe
6,465,433 Boronic ester and acid compounds, synthesis and uses► Subscribe
8,003,791Boronic ester and acid compounds, synthesis and uses► Subscribe
6,548,668 Boronic ester and acid compounds, synthesis and uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VELCADE

Country Document Number Estimated Expiration
Israel133831► Subscribe
Japan3717934► Subscribe
Hong Kong1087714► Subscribe
Spain2359391► Subscribe
Denmark2251344► Subscribe
European Patent Office1360189► Subscribe
European Patent Office1997823► Subscribe
Japan2004517932► Subscribe
Austria501157► Subscribe
European Patent Office0788360► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VELCADE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0788360/01Switzerland► SubscribeFORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
C0014France► SubscribePRODUCT NAME: BORTEZOMIB; REGISTRATION NO/DATE: EU/1/04/274/001 20040426
C008/2004Ireland► SubscribeSPC008/2004: 20050504, EXPIRES: 20190425
0151Netherlands► Subscribe300151, 20151027, EXPIRES: 20190425
C/GB04/021United Kingdom► SubscribePRODUCT NAME: BORTEZOMIB OR PHARMACEUTICALLY ACCEPTABLE ESTER THEREOF, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/274/001 20040428
083Luxembourg► Subscribe91083, EXPIRES: 20190426
2004 00012Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Cerilliant
Baxter
Julphar
Fuji
UBS
Healthtrust
McKinsey
Accenture
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot